Literature DB >> 8213634

Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature.

J Ordi1, J M Grau, A Junqué, B Nomdedeu, A Palacin, A Cardesa.   

Abstract

This article describes two patients with localized Castleman's disease (CD) of the mixed hyaline vascular and plasma cell type located at the mesentery of the small bowel, associated with systemic symptoms, anemia, an increased plasma level of acute phase reactants, and systemic amyloidosis. There were amyloid deposits on the vascular walls of the liver, spleen, and mesenteric lymphoid mass. On immunohistochemical studies, amyloid was shown to be of the AA type in both cases. After surgical resection of the mesenteric mass, clinical and laboratory manifestations improved, and the amyloidosis showed no progression in these patients 23 years and 1 year later. The authors' review of the literature shows a striking similarity of CD cases associated with amyloidosis in terms of the abdominal localization of the lymphoid mass, secondary pattern (AA type) of amyloidosis, and improvement of clinical manifestations after removal of the tumor, without progression of amyloid deposition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8213634     DOI: 10.1093/ajcp/100.4.394

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.

Authors:  S Ikeda; H Chisuwa; S Kawasaki; J Ozawa; Y Hoshii; T Yokota; T Aoi
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

2.  Castleman's disease imitating adrenal mass in the retroperitoneal area.

Authors:  Gökhan Koç; Hakan Turk; Sıtkı Un; Cemal Selcuk Isoglu; Ferruh Zorlu
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 3.  Waldenström's macroglobulinemia associated with AA amyloidosis.

Authors:  J Gardyn; A Schwartz; R Gal; U Lewinski; D Kristt; A M Cohen
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

4.  Marked hepatomegaly due to AA type amyloidosis in a case with Castleman's disease.

Authors:  Noboru Yamagata; Jyunko Fujio; Risen Hirai; Mutsumi Matsumaru; Satoshi Tanimura; Chiho Inokuchi; Tateki Shikai; Naoki Takezako; Michiyo Nasu; Yoichi Sakata; Naohiro Sata; Hideo Nagai; Ken Saito; Akiyoshi Miwa
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 5.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

6.  Systemic Reactive Amyloidosis Associated with Castleman's Disease.

Authors:  Vinaya Gaduputi; Hassan Tariq; Kanthi Badipatla; Ariyo Ihimoyan
Journal:  Case Rep Gastroenterol       Date:  2013-11-12

Review 7.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.